{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:43:10Z","timestamp":1792485790081,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Italian Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaut.2025.103487","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T23:33:47Z","timestamp":1758584027000},"page":"103487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial"],"prefix":"10.1016","volume":"157","author":[{"given":"Francesco","family":"Peyronel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Palmisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Maritati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Alberici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gianfreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni M.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paride","family":"Fenaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bettiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Moroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-9172","authenticated-orcid":false,"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9506","key":"10.1016\/j.jaut.2025.103487_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(06)68035-5","article-title":"Retroperitoneal fibrosis","volume":"367","author":"Vaglio","year":"2006","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaut.2025.103487_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.kint.2022.09.027","article-title":"Clinical phenotypes and long-term outcome of kidney involvement in Erdheim-Chester histiocytosis","volume":"103","author":"Chazal","year":"2023","journal-title":"Kidney Int."},{"issue":"7","key":"10.1016\/j.jaut.2025.103487_bib3","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1086\/433189","article-title":"Tuberculosis as a trigger of retroperitoneal fibrosis","volume":"41","author":"Greco","year":"2005","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.jaut.2025.103487_bib4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1093\/ndt\/gfaa083","article-title":"Idiopathic retroperitoneal fibrosis: an update for nephrologists","volume":"36","author":"Raglianti","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jaut.2025.103487_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3389\/fimmu.2019.00693","article-title":"Clinical and prognostic significance of serum IgG4 in chronic periaortitis. An analysis of 113 patients","volume":"10","author":"Maritati","year":"2019","journal-title":"Front. Immunol."},{"issue":"9976","key":"10.1016\/j.jaut.2025.103487_bib6","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(14)60720-0","article-title":"IgG4-related disease","volume":"385","author":"Kamisawa","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jaut.2025.103487_bib7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.autrev.2017.07.020","article-title":"Antineutrophil cytoplasmic antibody-associated vasculitides and IgG4-related disease: a new overlap syndrome","volume":"16","author":"Danlos","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"10.1016\/j.jaut.2025.103487_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1046\/j.1365-2796.2002.00948.x","article-title":"ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitis?","volume":"251","author":"Vaglio","year":"2002","journal-title":"J. Intern. Med."},{"issue":"9788","key":"10.1016\/j.jaut.2025.103487_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(11)60934-3","article-title":"Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial","volume":"378","author":"Vaglio","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaut.2025.103487_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1053\/j.ajkd.2007.02.268","article-title":"Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone","volume":"49","author":"van Bommel","year":"2007","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.jaut.2025.103487_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.ajkd.2019.04.020","article-title":"Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse","volume":"74","author":"Raffiotta","year":"2019","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.jaut.2025.103487_bib12","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1136\/annrheumdis-2013-203267","article-title":"Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis","volume":"72","author":"Alberici","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.jaut.2025.103487_bib13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2011-200148","article-title":"Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis","volume":"71","author":"Binder","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.jaut.2025.103487_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-154-1-201101040-00005","article-title":"Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series","volume":"154","author":"Scheel","year":"2011","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.jaut.2025.103487_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/annrheumdis-2019-216258","article-title":"Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients","volume":"79","author":"Urban","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.jaut.2025.103487_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.jaut.2025.103487_bib17","first-page":"1544","article-title":"Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis","volume":"41","author":"Vianello","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.jaut.2025.103487_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.2004.029793","article-title":"Immunosuppressive treatment of chronic periaortitis: a retrospective study of 20 patients with chronic periaortitis and a review of the literature","volume":"64","author":"Warnatz","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.jaut.2025.103487_bib19","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1038\/s41375-020-0944-4","article-title":"Erdheim-Chester disease: a rapidly evolving disease model","volume":"34","author":"Pegoraro","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jaut.2025.103487_bib20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e31826b1c1d","article-title":"Malignant retroperitoneal fibrosis: MRI characteristics in 50 patients","volume":"91","author":"Mirault","year":"2012","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.jaut.2025.103487_bib21","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.juro.2014.10.123","article-title":"The use of internal stents in chronic ureteral obstruction","volume":"193","author":"Fiuk","year":"2015","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.jaut.2025.103487_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 American college of rheumatology\/European league against rheumatism classification criteria for IgG4-related disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.jaut.2025.103487_bib24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1136\/annrheumdis-2018-214603","article-title":"Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts","volume":"78","author":"Wallace","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.jaut.2025.103487_bib25","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/ndt\/gfl228","article-title":"Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and\/or medical approaches","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.jaut.2025.103487_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.14712\/23362936.2016.3","article-title":"Combination of steroids and azathioprine in the treatment of ormond's disease--A single centre retrospective analysis","volume":"117","author":"Prucha","year":"2016","journal-title":"Prague Med. Rep."},{"issue":"7","key":"10.1016\/j.jaut.2025.103487_bib27","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.jaut.2025.103487_bib28","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1681\/ASN.2015101110","article-title":"Idiopathic retroperitoneal fibrosis","volume":"27","author":"Vaglio","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.jaut.2025.103487_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/bju.13915","article-title":"Contemporary role of ureterolysis in retroperitoneal fibrosis: treatment of last resort or first intent? An analysis of 50 cases","volume":"120","author":"O'Brien","year":"2017","journal-title":"BJU Int."},{"issue":"5","key":"10.1016\/j.jaut.2025.103487_bib30","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/1744666X.2023.2195627","article-title":"IgG4-related disease: advances in pathophysiology and treatment","volume":"19","author":"Peyronel","year":"2023","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"12","key":"10.1016\/j.jaut.2025.103487_bib31","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jaut.2025.103487_bib32","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T06:11:25Z","timestamp":1773123085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125001325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"alternative-id":["S0896841125001325"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103487","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103487","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103487"}}